Compare
Four compounds, four different economics
Mechanism, evidence maturity and regulatory status side by side — and why synthesis complexity, not marketing, drives most of the price spread.
How these four compounds differ
The four compounds on this site were chosen because they sit at genuinely different points on both the evidence-maturity axis and the synthesis-complexity axis, and those two axes explain most of what a reader needs to know before taking any claim about them at face value. Retatrutide and tirzepatide are large, chemically modified peptides built around the same fatty-diacid acylation strategy for a long half-life; tirzepatide has cleared FDA approval and carries the deepest published trial record of the group, while retatrutide is still in Phase 3 trials but has already shown larger weight-loss and liver-fat effects in Phase 2 data [3][4]. BPC-157 and CJC-1295 are both unapproved research chemicals with far thinner human evidence — BPC-157's human data are limited to three small pilot studies [14], and CJC-1295's human evidence is restricted to early pharmacology work in small groups of healthy adults [21][22].
Mechanism, side by side
| Compound | Category | Regulatory status | Evidence maturity | Primary research focus | Relative synthesis complexity |
|---|---|---|---|---|---|
| Retatrutide | Triple GIP/GLP-1/glucagon receptor agonist | Investigational (Phase 3) | Multiple published Phase 1/2 human trials [1][4][5][6] | Weight loss, liver fat, metabolic markers | High — fatty-diacid acylated, 39 residues |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | FDA-approved (T2D, obesity) | Deepest record of the four, incl. head-to-head trial [8][11][12] | Weight loss, glycemic control | High — fatty-diacid acylated, 39 residues |
| BPC-157 | Gastric-derived pentadecapeptide | Not approved anywhere | Overwhelmingly preclinical; 3 small human pilots [14] | Tissue repair, angiogenesis (animal models) | Low — short 15-residue linear chain |
| CJC-1295 | GHRH analog (DAC / no-DAC) | Not approved anywhere | Early-phase human pharmacology only [20][21][22] | GH/IGF-1 axis elevation | Moderate–High — DAC form adds albumin-binding linker |
Why the price gap tracks the evidence gap — and why it shouldn't be read as a guarantee
It is tempting to read a higher price as a stand-in for better quality, and a lower price as a warning sign — but the honest picture is more limited than that. Price differences across this group track synthesis complexity (a short 15-residue chain like BPC-157 is cheaper to make than a 39-residue fatty-acid-conjugated molecule like retatrutide or tirzepatide), purity-testing rigor, and cold-chain handling, none of which is visible on a product page. A cheap, short peptide can still be well-tested, and an expensive, complex one can still be poorly verified. The only way any of this becomes trustworthy is independent purity and identity testing — something no price point guarantees on its own. This is why every compound page on this site separates cited clinical findings from anecdotal community reports and from open safety questions: the label 'expensive' or 'cheap' tells you about manufacturing cost structure, not about what is actually in the vial.